Navigation Links
A simple therapy for brain injury
Date:6/26/2008

Severe brain injury due to blunt force trauma could be reduced by application of a simple polymer, Polyethylene glycol or PEG, mixed in sterile water and injected into the blood stream as reported in BioMed Central's Journal of Biological Engineering.

Andrew Koob and Richard Borgens from Purdue University, Indiana, performed experiments in rats which showed that PEG was effective in limiting damage if administered within four hours after the head injury. However, if treatment was delayed for a further two hours, the beneficial effects were lost. During the experiments, rats were injured with a falling weight and then PEG was administered fifteen minutes, two hours, four hours or six hours later. The authors then carried out a series of behavioural tests on the rats to determine the effectiveness of the PEG treatment.

According to Borgens "These data suggest that PEG may be clinically useful to victims of traumatic brain injury if delivered as rapidly as possible after an injury". Such a treatment could feasibly be carried out at the scene of an accident where PEG could be delivered as a component of IV fluids thus reducing long term brain injury.


'/>"/>

Contact: Graeme Baldwin
graeme.baldwin@biomedcentral.com
44-020-763-14804
BioMed Central
Source:Eurekalert

Page: 1

Related biology technology :

1. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
2. AMT Makes Important Advance in the Development of its Gene Therapy for Hemophilia B -Company Accesses Technology to Prevent Immune Response
3. Presentation at the 14th International Conference on Prenatal Diagnosis and Therapy Highlights Biocepts I.D.Rh(D) Prenatal Diagnostic
4. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
5. Investigational Studies Highlight Potential Utility of Zevalin(R) (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkins Lymphoma
6. Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy
7. First Taxane-Based Non-Anthracycline Containing Chemotherapy in Combination With Herceptin (TCH) for HER2 Positive Early Breast Cancer Patients Obtains Approval From the FDA
8. American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients
9. FDA Clears New Applicators for Endometrial Cancer Treatment With Xofts Axxent(R) Electronic Brachytherapy System
10. New Patient Satisfaction Study With budesonide/formoterol Combination Therapy and fluticasone/salmeterol Combination Therapy in Adults With Asthma
11. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology:
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):